Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2009

View Archived Issues

Escitalopram and tianepine show comparable efficacy in geriatric depression

QuatRx reports results from phase III Ophena trial in vulvovaginal atrophy

PET radioligand [18F]AZD-4694 displays favorable profile for detection of Abeta deposits

Merck Serono claims S1P1receptor antagonists for autoimmune and inflammatory disorders

Roche presents novel BTK inhibitors for the treatment of rheumatoid arthritis

University of Edinburgh reports new 11beta-HSD1 inhibitors

AstraZeneca developing new glucocorticoid receptor agonists for treatment of asthma

Plethora presents results for phase III PSD-502 trial in premature ejaculation

Neurocrine reports new 6-month data for elagolix in patients with endometriosis

Forma collaborates with Novartis on inhibitors of protein-protein interactions

GlaxoSmithKline withdraws MAA for Bosatria

OvPlex ovarian cancer diagnostic to be launched in the U.K. and Ireland

Lundbeck and Solvay discontinue development of bifeprunox in schizophrenia

Prima BioMed submits IND to FDA for CVac ovarian cancer therapy vaccine

Patient enrollment completed in phase IIb trial of HMPL-004 in UC

GenVec receives grant from NIAID to support malaria vaccine program

Anadys receives FDA clearance for phase II ANA-598 protocol

Phase II/III data support efficacy and tolerability of lurasidone in acute schizophrenia

Marplan shows potential in migraine prophylaxis in small open-label trial

Lopinavir/ritonavir has similar safety and efficacy in q.d. and b.i.d. dosing in HIV-1 patients

Jerini discloses preclinical data on its bradykinin B2 receptor antagonist JSM-10292

FDA approves Tyvaso inhalation solution for pulmonary arterial hypertension

AstraZeneca submits NDA and MAA for vandetanib in non-small cell lung cancer

Cytos reports phase II CYT003-QbG10 monotherapy results in dust mite allergy

Transave enters into agreement with NIH for Arikace in mycobacteria infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...